Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EVALUATION OF S12363, A NOVEL VINCA ALKALOID DRUG IN THE TREATMENT OFADVANCED MALIGNANT-MELANOMA - A PHASE-II STUDY
Autore:
STANLEY AJ; KAPRIELIAN R; RETSAS S;
Indirizzi:
WESTMINSTER MED SCH & HOSP,CHARING CROSS & WESTMINSTER MED SCH,MED ONCOL UNIT LONDON SW1P 2AP ENGLAND WESTMINSTER MED SCH & HOSP,CHARING CROSS & WESTMINSTER MED SCH,MED ONCOL UNIT LONDON SW1P 2AP ENGLAND
Titolo Testata:
Anticancer research
fascicolo: 1, volume: 13, anno: 1993,
pagine: 31 - 32
SICI:
0250-7005(1993)13:1<31:EOSANV>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Keywords:
S12363; CLINICAL PHASE-II STUDY; MALIGNANT MELANOMA;
Tipo documento:
Article
Natura:
Periodico
Citazioni:
5
Recensione:
Indirizzi per estratti:
Citazione:
A.J. Stanley et al., "EVALUATION OF S12363, A NOVEL VINCA ALKALOID DRUG IN THE TREATMENT OFADVANCED MALIGNANT-MELANOMA - A PHASE-II STUDY", Anticancer research, 13(1), 1993, pp. 31-32

Abstract

We conducted a phase II study with the new vinca alkaloid derivative S12363 in ten patients with metastatic malignant melanoma. Six patients had been pre-treated with other cytotoxic agents and all had received Vindesine. Four patients had no prior systemic treatment before entry into the study. S12363 was well tolerated subjectively, the main toxicity being haematological. Despite encouraging in vitro observations,no objective responses to S12363 have been documented in these patients with the doses and schedule used in this study. S12363 appears to have no clinically useful activity in metastatic malignant melanoma.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/07/20 alle ore 12:24:33